Published in Trends Genet on October 22, 2015
An integrated encyclopedia of DNA elements in the human genome. Nature (2012) 64.73
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
Selective inhibition of BET bromodomains. Nature (2010) 18.79
The accessible chromatin landscape of the human genome. Nature (2012) 16.86
Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev (2011) 16.77
The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell (1996) 16.57
Requirement of bic/microRNA-155 for normal immune function. Science (2007) 16.24
The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res (2012) 15.41
Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet (2012) 15.21
Systematic localization of common disease-associated variation in regulatory DNA. Science (2012) 14.47
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A (2005) 12.96
Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell (2008) 12.29
A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell (2010) 12.27
Regulation of the germinal center response by microRNA-155. Science (2007) 12.25
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med (2004) 12.20
A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer (2011) 11.33
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet (2010) 10.97
Integrative analysis of 111 reference human epigenomes. Nature (2015) 10.32
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature (2011) 9.71
Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell (2013) 9.55
CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell (2013) 9.55
MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell (2007) 9.33
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell (2013) 9.24
Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell (2013) 8.37
Modular regulatory principles of large non-coding RNAs. Nature (2012) 7.42
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A (2012) 7.14
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature (2012) 7.01
microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity (2007) 6.72
An atlas of active enhancers across human cell types and tissues. Nature (2014) 6.57
Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A (2011) 6.30
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell (2003) 6.11
Long noncoding RNAs: cellular address codes in development and disease. Cell (2013) 6.01
Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med (2001) 5.66
Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet (2013) 5.48
Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature (2011) 5.20
Binding and modulation of p53 by p300/CBP coactivators. Nature (1997) 5.12
MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocation. Immunity (2008) 5.03
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med (2001) 4.83
The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell (2010) 4.71
Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood (2010) 4.02
Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nat Biotechnol (2015) 3.56
Synergistic and tunable human gene activation by combinations of synthetic transcription factors. Nat Methods (2013) 3.26
Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev (2000) 3.24
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell (2013) 3.13
Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell (2013) 3.13
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov (2014) 3.09
Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet (2012) 3.08
The genetic landscape of mutations in Burkitt lymphoma. Nat Genet (2012) 3.03
The rise of regulatory RNA. Nat Rev Genet (2014) 3.02
Acetylation inactivates the transcriptional repressor BCL6. Nat Genet (2002) 3.00
Integrative annotation of variants from 1092 humans: application to cancer genomics. Science (2013) 2.98
Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression. Nat Genet (2012) 2.86
A prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin binding. Nat Genet (2014) 2.60
Pathogenesis of human B cell lymphomas. Annu Rev Immunol (2012) 2.44
The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol (2005) 2.42
microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood (2010) 2.37
Cell-of-origin chromatin organization shapes the mutational landscape of cancer. Nature (2015) 2.35
Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas. Blood (2012) 2.30
Epigenomic enhancer profiling defines a signature of colon cancer. Science (2012) 2.15
Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell (2014) 2.15
Combinatorial effects of multiple enhancer variants in linkage disequilibrium dictate levels of gene expression to confer susceptibility to common traits. Genome Res (2013) 2.14
EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood (2010) 2.11
Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis. Proc Natl Acad Sci U S A (2010) 2.07
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A (2013) 2.00
New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood (2008) 1.97
Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet (2013) 1.93
RNA-mediated epigenetic regulation of gene expression. Nat Rev Genet (2015) 1.90
Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet (2013) 1.85
The long intergenic noncoding RNA landscape of human lymphocytes highlights the regulation of T cell differentiation by linc-MAF-4. Nat Immunol (2015) 1.82
Identification and consequences of miRNA-target interactions--beyond repression of gene expression. Nat Rev Genet (2014) 1.79
miR-181b negatively regulates activation-induced cytidine deaminase in B cells. J Exp Med (2008) 1.77
DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. Blood (2010) 1.77
Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma. Clin Cancer Res (2014) 1.75
Genetics of follicular lymphoma transformation. Cell Rep (2014) 1.70
Pathogenesis of follicular lymphoma. J Clin Invest (2012) 1.66
DNA methylation contributes to natural human variation. Genome Res (2013) 1.66
Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood (2014) 1.64
Array-based DNA methylation profiling in follicular lymphoma. Leukemia (2009) 1.63
Dynamics of B cells in germinal centres. Nat Rev Immunol (2015) 1.61
MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. Br J Haematol (2008) 1.60
B cell super-enhancers and regulatory clusters recruit AID tumorigenic activity. Cell (2014) 1.58
MicroRNA-155 controls RB phosphorylation in normal and malignant B lymphocytes via the noncanonical TGF-β1/SMAD5 signaling module. Blood (2013) 1.52
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol (2008) 1.49
The Landscape of long noncoding RNA classification. Trends Genet (2015) 1.47
Convergent transcription at intragenic super-enhancers targets AID-initiated genomic instability. Cell (2014) 1.43
Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nat Genet (2014) 1.41
Integrative analysis of haplotype-resolved epigenomes across human tissues. Nature (2015) 1.40
Mantle cell lymphoma: evolving management strategies. Blood (2014) 1.38
DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia (2014) 1.38
Germinal centres and B cell lymphomagenesis. Nat Rev Immunol (2015) 1.34
A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters. Cell Rep (2013) 1.28
MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood (2014) 1.19
Functional annotation of colon cancer risk SNPs. Nat Commun (2014) 1.19
Enhancer malfunction in cancer. Mol Cell (2014) 1.19
Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth. Chem Biol (2013) 1.18
Regulation of immune responses and tolerance: the microRNA perspective. Immunol Rev (2013) 1.18
EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood (2013) 1.17
miRNA profiling of B-cell subsets: specific miRNA profile for germinal center B cells with variation between centroblasts and centrocytes. Lab Invest (2009) 1.16